Author's response to reviews

Title: Nail changes secondary to Docetaxel chemotherapy

Authors:

Qamar Ghafoor (qamar.ghafoor@uhb.nhs.uk)
Anula Chetiyawardana (anula.chetiyawardana@uhb.nhs.uk)

Version: 4 Date: 14 December 2007

Author's response to reviews:

Dear Sir,
We are resubmitting our edited case report following alterations made after peer review.
As Kent Yip appeared to be happy with the article we have not made any changes from his comments.
We have taken comments made by In Sook Woo on board. We have subsequently included more information regarding grading of nail toxicity, and the ensuing management.
We would also like the opportunity to respond to some of the comments.
We agree that nail changes secondary to taxane chemotherapy is a recognised complication of the treatment. It is reasonably well known amongst the oncology community. However, to general physicians and family practitioners it is not a recognised cause of nail damage. From experience in our large teaching unit, we have had a significant number of queries and concerns from this population of medical professionals.
In the UK, 20 to 30 percent of patients receiving chemotherapy are likely to receive a taxane agent at some time. This makes up a substantial number of patients.
Your journal is widely accessed in the UK (and I suspect worldwide) by general physicians and family practitioners. By highlighting this problem, we feel that we can not only help from educational needs, but also improve patient care.
We hope that you find this resubmission acceptable.
Many thanks